Sanara MedTech (NASDAQ:SMTI – Get Free Report) and ReWalk Robotics (NASDAQ:LFWD – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.
Insider and Institutional Ownership
8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 26.8% of ReWalk Robotics shares are owned by institutional investors. 54.1% of Sanara MedTech shares are owned by insiders. Comparatively, 2.5% of ReWalk Robotics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Sanara MedTech and ReWalk Robotics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sanara MedTech | $64.99 million | 4.99 | -$4.30 million | ($0.99) | -37.49 |
| ReWalk Robotics | $13.85 million | 1.03 | -$22.13 million | ($2.49) | -0.65 |
Profitability
This table compares Sanara MedTech and ReWalk Robotics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sanara MedTech | -10.71% | -19.86% | -10.91% |
| ReWalk Robotics | -77.21% | -43.02% | -31.53% |
Analyst Recommendations
This is a breakdown of current ratings for Sanara MedTech and ReWalk Robotics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sanara MedTech | 0 | 0 | 2 | 0 | 3.00 |
| ReWalk Robotics | 0 | 0 | 1 | 1 | 3.50 |
Sanara MedTech presently has a consensus target price of $47.00, indicating a potential upside of 26.62%. ReWalk Robotics has a consensus target price of $13.00, indicating a potential upside of 702.47%. Given ReWalk Robotics’ stronger consensus rating and higher possible upside, analysts plainly believe ReWalk Robotics is more favorable than Sanara MedTech.
Risk and Volatility
Sanara MedTech has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, ReWalk Robotics has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500.
Summary
Sanara MedTech beats ReWalk Robotics on 9 of the 15 factors compared between the two stocks.
About Sanara MedTech
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
About ReWalk Robotics
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.
Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.
